Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
81 results about "Pulmonary inflammation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Lung (pulmonary) inflammation affects the airways and lung tissue. Caused by the body’s immune response to injury or pathogens, inflammation can be acute (short-lasting) or chronic (long-lasting) in nature. Diseases associated with acute lung inflammation include acute lung infections, pneumonia, and acute respiratory distress syndrome (ARDS).
Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
InactiveUS20080170990A1Ultrasonic/sonic/infrasonic diagnosticsOrganic active ingredientsBronchospasmCardiac muscle
The present application discloses methods for myocardial imaging in human patients having a history of pulmonary disease such as asthma, bronchospasm, chronic obstructive pulmonary disease, pulmonary fibrosis, pulmonary inflammation, or pulmonary hypertension, comprising administrating doses of one or more A2A adenosine receptor agonists to a mammal undergoing myocardial imaging and detecting and / or diagnosing myocardial dysfunction.
Owner:TPG AXON LEX SUB TRUST +1
A2B adenosine receptor antagonists
ActiveUS20050119287A1Amenable to treatmentAvoid actionOrganic active ingredientsBiocideNeurological disorderDisease cause
Disclosed are novel compounds that are A2B adenosine receptor antagonists having the following structure: wherein R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological / inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.
Owner:GILEAD SCI INC
Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
InactiveUS7056898B2Relieve symptomsOvercomes shortcomingOrganic active ingredientsBiocideAllergyPathology diagnosis
Provided are compounds and compositions thereof that are useful for treating inflammation, particularly pulmonary inflammations including asthma and asthma-related pathologies such as allergy. Also provided are methods for using such compounds and compositions of the invention to treat patients suffering from, or predisposed to develop inflammation.
Owner:TEVA WOMENS HEALTH RES INC
Use of aerosolized antithrombin to treat acute lung injury
InactiveUS20050169908A1Effective treatmentReduced gas exchangePeptide/protein ingredientsAerosol deliveryDiseaseALI - Acute lung injury
The invention features methods of treating a subject having a lung disorder such as lung inflammation and injury, by administering antithrombin III through pulmonary delivery.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
InactiveUS20030087875A1Treating and alleviating symptomRelieve symptomsOrganic active ingredientsBiocideMedicineAllergy
Provided are compounds and compositions thereof that are useful for treating information, particularly pulmonary inflammations including asthma and asthma-related pathologies such as allergy. Also provided are methods for using such compounds and compositions of the invention to treat patients suffering from, or predisposed to develop inflammation.
Owner:TEVA WOMENS HEALTH RES INC
Fusion protein of porcine reproductive and respiratory syndrome virus as PRRS vaccine
ActiveUS20080008722A1SsRNA viruses positive-senseVirus peptidesPseudomonas aeruginosa exotoxin AAllergy
The present invention provides a PRRSV subunit vaccine comprising a fusion protein having neutralization titers evoked, PE-PQGAB-K3, which comprises a chimeric polypeptide containing N-terminal portions of PRRSV ORF5 and ORF6 structure proteins; a portion of Pseudomonas exotoxin A binding and translocation domain; and a carboxyl terminal domain containing KDEL-KDEL-KDEL(K3) sequence. Less inflammation of PE-PQGAB-K3 vaccine group in their lungs post being PRRSV-challenged indicates that PQGAB without an antigen-specific allergy effect. Importantly, PE-PQGAB-K3 vaccine presents a good protection against PRRSV infection than control groups in pig challenged experiment.
Owner:AGRI TECH RES INST
Markers for diagnosis of pulmonary inflammation and methods related thereto
Owner:NAT JEWISH HEALTH
Markers for Diagnosis of Pulmonary Inflammation and Methods Related Thereto
The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.
Owner:NAT JEWISH HEALTH
Bi-functional pyrazolopyridine compounds
This invention provides compounds of the formula:wherein X iswherein R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring and all other variables are as defined herein, their use in pulmonary inflammation or bronchoconstriction therapy and compositions comprising and processes for preparing the same are provided.
Owner:GILEAD SCI INC
IL-18 and Protein Kinase R Inhibition for the Treatment of COPD
InactiveUS20100247538A1Reduce expressionPrevents and dysregulationOrganic active ingredientsPeptide/protein ingredientsCOPDProtein kinase R
The present invention encompasses compositions and methods directed to preventing, inhibiting, or treating inflammation, alveolar remodeling, or cell death in lung which results from elevation of IL-18, IFN-γ, or PKR where the methods of the present invention comprise administering an IL-18 inhibitor, an IL-18Rα inhibitor, and IFNγ inhibitor, a PKR inhibitor, and any combination thereof to an individual experiencing inflammation, alveolar remodeling, or cell death in lung. The present invention further encompasses a method of alleviating exacerbations of COPD frequently caused by viral infection by administering inflammation, alveolar remodeling, or cell death in lung to a patient with COPD at risk of developing a viral infection or who has acquired a viral infection.
Owner:YALE UNIV
Bi-functional quinoline analogs
Provided are compounds of Formula I:wherein X is:R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring, and all other variables are as defined herein, as well as their use in treating pulmonary inflammation or bronchoconstriction and compositions comprising and processes for preparing the same.
Owner:GILEAD SCI INC
Compositions for treatment and prevention of pulmonary conditions
InactiveUS7863241B2Increase volumeDecreasing amountBiocidePeptide/protein ingredientsDiseasePhospholipase inhibitor
The invention provides compositions and methods for treating pulmonary conditions and for reducing the negative effects of pulmonary inflammation. Such compositions and methods employ protease inhibitors and a lung surfactant mixture. The compositions and methods can also include lipase inhibitors (e.g. a phospholipase inhibitors) and anti-oxidants.
Owner:THE SCRIPPS RES INST
Chinese medicinal composition and application of drug containing the same to treating avian influenza
ActiveCN101569700AObvious anti-avian influenza virus effectReduce mortalityAntiviralsUnknown materialsMortality rateToxic material
The invention relates to a Chinese medicinal composition and application of a drug containing the same to treating avian influenza. Various preparations containing the Chinese medicinal composition can effectively prevent and control the avian influenza. An anti-avian influenza animal screening test is performed to screen protective action of the Chinese medicinal composition on mice infected with H5N1 and H9N2 strains respectively, and the Chinese medicinal composition can obviously inhibit pulmonary inflammation of the mice caused by avian influenza viruses, reduce death rate of the mice infected with the avian influenza viruses and prolong survival time of the mice, and has obvious avian influenza resistance. The medicinal composition is made from the following herbs: dandelion, Chinese violet, baikal skullcap root, holly root, red peony root, radix trichosanthis, figwort, angelica, ledebouriella root, bupleurum root, Chinese honeylocust spine, artificial cow-bezoar, dahurian angelica, arisaema with bile, giant knotweed, ptunella spike and isatis root. The herbs are combined to allow various herbs to produce synergetic efficacy, and the Chinese medicinal composition has efficacy of clearing away heat and toxic material, activating blood circulation and cooling blood, relieving inflammation and pain.
Owner:GUANGDONG ZHONGSHENG PHARMA
Antagonistic drug against replication of porcine reproductive and respiratory syndrome virus (PRRSV) and application of antagonistic drug
ActiveCN110613706AInhibition of replicationStrong replicabilityOrganic compound preparationKetone active ingredientsPlant SourcesTherapeutic effect
The invention discloses an antagonistic drug against replication of a porcine reproductive and respiratory syndrome virus (PRRSV) and application of the antagonistic drug. A virus infection test is adopted, and Xanthohumol (Xn), the antagonistic drug of the PRRSV, is discovered for the first time from a natural medicine library with 386 plant sources. The drug can effectively inhibit PRRSV replication in both Marc-145 and PAM cells, five xanthohumol derivatives with different molecular structures are artificially synthesized, and the viral infection test further finds that the inhibition effect to virus replication by drug derivative Xn-4 is highest in vitro; and test results of artificial infection and drug therapy in piglets show that the Xn-4 can effectively inhibit PRRSV viremia, relieves clinical symptoms of infected pigs, and significantly reduces pulmonary inflammation and pathological damage. Combined with the results, it is proved that the antagonistic drug has important preventive and therapeutic effects to a porcine reproductive and respiratory syndrome, and has important application prospects.
Owner:NANJING AGRICULTURAL UNIVERSITY
Application of mannose in the preparation of medicine for treating pulmonary inflammation disease
InactiveCN101095688AExpansion of new uses of medicinePrevent adverse side effectsOrganic active ingredientsAerosol deliveryDiseaseLung tissue
The invention provides the application of carubinose in preparing medicine that can treat lung acute inflammation diseases. The molecular formula of carubinose is C6H12O6, the structure is D-carubinose. Said medicine comprises medicine acceptable shaping agent or carrying agent. The produced dosage form mainly comprises liquid dosage form, granule, tablet, gas spraying form, drop or pill. The invention can reduce the lung tissue TNF-alpha level of mice ALT model induced by LPS, release neutral granulocyte wettability in lung tissue, inhibit capillary blood permeability, decrease protein exudation and lung water content, reduce MPO level in BALF supernatant and improve pathologic change for lung tissue inflammation. The invention discloses the functions of anti-inflammation, anti-oxidation and pneumochysis reduction of carubinose.
Owner:ZHEJIANG UNIV
Compositions and methods for promoting vascular barrier function and treating pulonary fibrosis
InactiveUS20120129757A1Promote vascular barrier functionEnhanced barrier functionAntibacterial agentsBiocideVascular endothelium permeabilityActive agent
Active agents and compositions that promote barrier function or that inhibit permeability of the vascular endothelium associated with pulmonary inflammation are described.
Owner:THE UNIV OF UTAH
Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
Owner:IONIS PHARMA INC
Substituted phenylphosphates as mutual prodrugs of steroids and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
Owner:GILEAD SCI INC
Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
InactiveUS8158110B2Easy to controlLow toxicityAntibacterial agentsBiocideDiseaseInflammation Process
Owner:UNIVERSITY OF PITTSBURGH
Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
Owner:SCHERING CORP
Application of physically-modified cobra venom in preparation of medicament for treating pulmonary fibrosis
InactiveCN102526114ALow toxicityImprove efficacyReptile material medical ingredientsRespiratory disorderDiseaseCobra venom
The invention discloses application of cobra venom in preparation of a medicament for treating lung inflammatory disease and pulmonary fibrosis. Animal experiment proves that Chinese cobra venom can alleviate acute endotoxin poisoning symptom within a range of 10-3000mug / kg, particularly has obvious therapeutic action on lung inflammatory disease caused by endotoxin, and can be used for alleviating inflammatory cell infiltration, alveolar septum thickening, and focal atelectasis and emphysema. Repeated small dose of endotoxin can result in pulmonary fibrosis, the cobra venom can significantly alleviate pulmonary fibrosis symptom and reduce alveoli damage and collagen hyperplasia. Naturally-modified Chinese cobra venom and physically-modified Chinese cobra venom have similar actions, but the physically-modified Chinese cobra venom has better action. Used for treating lung inflammatory disease, the Chinese cobra venom has the advantages of low dose, safety, capability of being orally administrated, injected, and administered through oral mucous membrane and skin and the like.
Owner:SUZHOU RENBEN PHARMA
Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction
InactiveUS20100098641A1Improve hydrophilicityImparts its affinityAerosol deliveryRespiratory disorderBeta-Adrenergic AgonistPulmonary inflammation
Owner:GILEAD SCI INC
Application of naringenin in preparation of medicine for curing pneumonia
The invention relates to the application of naringenin in the preparation of medicine for curing pneumonia. The effect in staphylococcus aureus infection curing is proved through a rabbit erythrocyte hemolytic test, a pulmonary epithelial cell (A549) damage protection test and a mouse staphylococcus aureus pulmonary inflammation model. Compared with antibiotic therapy, naringenin therapy has the characteristics of no drug tolerance and high cure rate.
Owner:HUBEI WUDANG ANIMAL PHARMA
Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
Disclosed are novel compounds that are A2B adenosine receptor antagonists having the following structure:wherein R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological / inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.
![Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A<sub>2b </sub>adenosine receptor antagonists](https://images-eureka.patsnap.com/patent_img/a24468a4-0a54-4f86-9a63-434a24439a24/US07449473-20081111-C00001.png "Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A<sub>2b </sub>adenosine receptor antagonists")
![Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A<sub>2b </sub>adenosine receptor antagonists](https://images-eureka.patsnap.com/patent_img/a24468a4-0a54-4f86-9a63-434a24439a24/US07449473-20081111-C00002.png "Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A<sub>2b </sub>adenosine receptor antagonists")
![Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A<sub>2b </sub>adenosine receptor antagonists](https://images-eureka.patsnap.com/patent_img/a24468a4-0a54-4f86-9a63-434a24439a24/US07449473-20081111-C00003.png "Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A<sub>2b </sub>adenosine receptor antagonists")
Owner:GILEAD SCI INC
P2X7 receptor imaging agent and preparation method thereof
InactiveCN109400605AImprove bindingThe synthesis process is simple and fastIsotope introduction to heterocyclic compoundsRadioactive preparation carriersMedicineImaging agent
The invention discloses a F-18 tagged P2X7 receptor imaging agent which is a compound 18F-{(2-chloro-3-trifluorophenyl)(1-(pyrimidin-2-yl)-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone shown as formula I. The P2X7 receptor imaging agent is suitable for identifying and diagnosing pulmonary inflammation and tumors.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
Application of traditional Chinese medicine composition in preparation of drugs for adjuvant therapy of novel coronavirus pneumonia
PendingCN112353855AImprove clinical symptomsImprove the effect of adjuvant therapyAntiviralsFungi medical ingredientsNausea sicknessAdjuvant therapy
The invention discloses an application of a traditional Chinese medicine composition in preparation of drugs for adjuvant therapy of novel coronavirus pneumonia. The traditional Chinese medicine composition comprises the raw materials: radix puerariae, radix scutellariae, rhizoma coptidis and radix glycyrrhizae preparata. Pneumonia patients infected by novel coronavirus mainly show fever, cough, dyspnea and the like, and part of the pneumonia patients can also show digestive system symptoms such as poor appetite, nausea, emesis, diarrhea and the like. Clinical experiments find that the traditional Chinese medicine composition has a good adjuvant therapy effect on novel coronavirus pneumonia in combination with conventional therapy, can quickly stabilize the condition of an illness, and particularly has a more obvious effect on improving cough, chest distress, nausea, vomiting, loose stool and the like. The average antipyretic time is 3 days, the average nucleic acid negative conversiontime is 8 days, and the clinical cure rate is 100%. The traditional Chinese medicine composition disclosed by the invention can block the conversion of mild and common pneumonia patients into severeand critical pneumonia patients; clinical symptoms of patients can be actively improved; lung inflammatory absorption can be well promoted; safe and reliable use is achieved.
Owner:广西壮族自治区花红药业集团股份公司
PGE-M as a biomarker of pulmonary inflammation
Abstract of the DisclosureThe invention provides a method of, and a kit for, assessing a pulmonary abnormality in a human by providing a standard that relates a degree of pulmonary abnormality with a level of a prostaglandin E2 metabolite, determining the level of the prostaglandin E2 metabolite in a human, and comparing the level determined in the human to the standard whereby the pulmonary abnormality in the human is assessed.
Owner:CORNELL RES FOUNDATION INC
Effect of atorvastatin on preparation of drug for treating pulmonary hypertension
InactiveCN103690532AEase reconstructionInhibit the inflammatory responseAntipyreticAnalgesicsRight ventricular hypertrophyHigh pressure
The invention relates to a new use of a drug, and specifically relates to an effect of atorvastatin on preparation of a drug for treating pulmonary hypertension. The invention discovers for the first time that atorvastatin is capable of alleviating MCT (Monocrotaline)-induced pulmonary inflammation, and inhibiting pulmonary vascular remodeling, pulmonary artery rising and right ventricular hypertrophy without affecting the body circulating pressure; NF-kB is possible to play an important role in the MCT-induced pulmonary hypertension; the atorvastatin is capable of inhibiting the inflammatory reaction by reducing the expression of the MCT-induced pulmonary hypertension lung tissue NF-kB, and is capable of reducing pulmonary vascular remodeling and inhibiting the pulmonary artery high pressure rising; therefore, the atorvastatin can be applied to preparation of the drug for treating the pulmonary hypertension.
Owner:邢西迁
Compositions and their uses directed to il-4r alpha
Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-α, airway hyperresponsiveness, and / or pulmonary inflammation.
Owner:IONIS PHARMA INC
Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction
InactiveUS20100209508A1Minimizing rapid systemic absorptionMinimal activity of enzymeOrganic active ingredientsPowder deliveryAgonistAerosolization
A mutual prodrug of a corticosteroid and a substituted phenylphosphate (β-agonist derivative) for formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between 5.0 and 7.0 for the treatment of respiratory tract inflammation and bronchoconstriction by an aerosol having mass median average diameter predominantly between 1 to 5μ, produced by nebulization or by dry powder inhaler.
Owner:GILEAD SCI INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com